The two designed compounds, dubbed NG1 and DN1, effectively treated N. gonorrhoeae and S. aureus respectively in preclinical models.

Dementia-like protein clumps found in pancreatic precancer mouse cells point to autophagy defects, offering cancer ...

Researchers demonstrate that an engineered antibody improves a class of drugs that has struggled to make good on its early promise.

Schrödinger has halted development of its cancer-fighting candidate SGR-2921 after two patients treated with the CDC7 inhibitor died in a Phase I trial.

Peptidoglycan hydrolases killed living bacteria, opening the door for further research into the interplay between archaea and bacteria.

PepMLM generates binders to challenging therapeutic targets across cancer and neurological disease using protein sequence and ...

Researchers say work lays the foundation for a first-line, deployable antiviral platform that is virus agnostic and modular.

Antimicrobial resistance studies often focus on individual protein variants, neglecting broader protein family dynamics. Dihydrofolate reductase (DHFR), a key antibiotic target, has been extensively ...

The current $195 million investment is part of a commitment to invest more than $10 billion for innovation and manufacturing capacity enhancement.

An oxygen-generating implant keeps high-density insulin-producing cells alive in diabetic rats for months without immune suppression.

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

Model serves as platform for understanding how chronic inflammation related to alcohol consumption accelerates pancreatic cancer development.